Adia Med Finalizing In-Network Access with the Nation's Largest Health Insurers Including Medicare, Medicaid, Humana, Cigna, and Florida Blue
Adia Nutrition Inc. (OTCQB: ADIA) is finalizing in-network provider status with major health insurance companies including Humana, Florida Blue, Cigna, Medicare, and Medicaid. This strategic move aims to expand patient access to the company's regenerative stem cell therapies.
The company has already submitted applications to Humana and Cigna, initiated the process with Florida Blue, and is actively pursuing Medicare and Medicaid access. This development builds upon Adia's recent partnership with the PI Doctors Elite Community, which connects Adia Labs with over 4,000 personal injury physicians nationwide.
Adia Nutrition Inc. (OTCQB: ADIA) sta completando l'accreditamento come fornitore convenzionato con importanti compagnie assicurative, tra cui Humana, Florida Blue, Cigna, Medicare e Medicaid. Questa mossa strategica punta ad ampliare l'accesso dei pazienti alle terapie rigenerative a base di cellule staminali dell'azienda.
L'azienda ha già presentato domanda a Humana e Cigna, ha avviato le pratiche con Florida Blue e sta lavorando per ottenere l'accesso tramite Medicare e Medicaid. Questo sviluppo si basa sulla recente collaborazione di Adia con la PI Doctors Elite Community, che mette in rete Adia Labs con oltre 4.000 medici specializzati in lesioni personali a livello nazionale.
Adia Nutrition Inc. (OTCQB: ADIA) está ultimando su incorporación como proveedor en la red de importantes aseguradoras, incluyendo a Humana, Florida Blue, Cigna, Medicare y Medicaid. Esta decisión estratégica busca ampliar el acceso de los pacientes a las terapias regenerativas con células madre de la compañía.
La empresa ya ha presentado solicitudes a Humana y Cigna, ha iniciado el proceso con Florida Blue y está gestionando el acceso a Medicare y Medicaid. Este avance se apoya en la reciente alianza de Adia con la PI Doctors Elite Community, que conecta a Adia Labs con más de 4.000 médicos de lesiones personales en todo el país.
Adia Nutrition Inc. (OTCQB: ADIA)는 Humana, Florida Blue, Cigna, Medicare, Medicaid 등 주요 보험사와의 네트워크 내 공급자 지위를 마무리하고 있습니다. 이러한 전략적 조치는 회사의 재생 줄기세포 치료법에 대한 환자 접근성을 확대하는 것을 목표로 합니다.
회사는 이미 Humana와 Cigna에 신청서를 제출했으며 Florida Blue와의 절차를 시작했고 Medicare 및 Medicaid 접근 권한도 적극적으로 추진 중입니다. 이 성과는 Adia Labs를 전국의 4,000명 이상의 개인상해 전문의와 연결하는 PI Doctors Elite Community와의 최근 파트너십을 바탕으로 합니다.
Adia Nutrition Inc. (OTCQB: ADIA) finalise son statut de prestataire dans le réseau de grandes compagnies d'assurance, notamment Humana, Florida Blue, Cigna, Medicare et Medicaid. Cette démarche stratégique vise à élargir l'accès des patients aux thérapies régénératives à base de cellules souches de la société.
L'entreprise a déjà déposé des demandes auprès de Humana et Cigna, a entamé les démarches avec Florida Blue et cherche activement à obtenir l'accès via Medicare et Medicaid. Cette évolution s'appuie sur le récent partenariat d'Adia avec la PI Doctors Elite Community, qui relie Adia Labs à plus de 4 000 médecins spécialisés en blessures corporelles à l'échelle nationale.
Adia Nutrition Inc. (OTCQB: ADIA) arbeitet daran, den Status als Vertragsanbieter bei großen Krankenversicherern wie Humana, Florida Blue, Cigna, Medicare und Medicaid abzuschließen. Dieser strategische Schritt soll den Patientenzugang zu den regenerativen Stammzelltherapien des Unternehmens ausweiten.
Das Unternehmen hat bereits Anträge bei Humana und Cigna gestellt, den Prozess mit Florida Blue gestartet und verfolgt aktiv den Zugang zu Medicare und Medicaid. Diese Entwicklung baut auf Adias jüngster Partnerschaft mit der PI Doctors Elite Community auf, die Adia Labs landesweit mit über 4.000 Ärzten für Personenschäden vernetzt.
- None.
- Insurance approval processes still pending with no guaranteed acceptance
- Timeline for final approvals remains uncertain
Winter Park, Florida--(Newsfile Corp. - September 2, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a rising name in regenerative medicine, is thrilled to announce a transformative step toward expanding patient access to its innovative stem cell therapies. The company is finalizing in-network provider status with some of the nation's largest health insurance providers-Humana, Florida Blue, Cigna, Medicare, and Medicaid-positioning Adia to bring its advanced treatments to millions of patients.
Expanding Access to Revolutionary Care
Adia Nutrition is making significant progress in securing in-network status, a critical move to make its regenerative therapies more accessible and affordable. Current developments include:
- Humana: Application submitted, awaiting response.
- Florida Blue: Process initiated, provider numbers in progress.
- Cigna: Application submitted, response pending.
- Medicare: Access pending, actively in progress.
- Medicaid: Access pending, actively in progress.
This milestone will enhance Adia's ability to deliver its therapies, including those for widely covered treatments like wound repair, to a broader patient base, building on its recent partnership with the PI Doctors Elite Community, connecting Adia Labs with over 4,000 personal injury physicians nationwide.
A Vision for Accessible Healing
"Joining these major insurance networks will open doors for countless patients to experience our regenerative therapies," said Larry Powalisz, CEO of Adia Nutrition Inc. "We're excited to make this a reality, helping people heal and growing value for our investors."
Join the Regenerative Revolution
Adia Nutrition is dedicated to transforming healthcare by making regenerative solutions more accessible. Stay tuned for updates as we advance toward in-network approval with these major insurers.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264752